Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

NCT04134325 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Hodgkin Lymphoma
Refractory Hodgkin Lymphoma

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Pembrolizumab

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]